ALBENDAZOLE Drug Patent Profile
✉ Email this page to a colleague
When do Albendazole patents expire, and when can generic versions of Albendazole launch?
Albendazole is a drug marketed by Actavis Elizabeth, Alembic, Chartwell Rx, Cipla Ltd, Dr Reddys, Edenbridge Pharms, MSN, Strides Pharma, and Zydus Pharms. and is included in nine NDAs.
The generic ingredient in ALBENDAZOLE is albendazole. There are ten drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the albendazole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Albendazole
A generic version of ALBENDAZOLE was approved as albendazole by ZYDUS PHARMS on December 14th, 2018.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ALBENDAZOLE?
- What are the global sales for ALBENDAZOLE?
- What is Average Wholesale Price for ALBENDAZOLE?
Summary for ALBENDAZOLE
| US Patents: | 0 |
| Applicants: | 9 |
| NDAs: | 9 |
| Finished Product Suppliers / Packagers: | 16 |
| Raw Ingredient (Bulk) Api Vendors: | 157 |
| Clinical Trials: | 119 |
| Patent Applications: | 4,160 |
| Drug Prices: | Drug price information for ALBENDAZOLE |
| What excipients (inactive ingredients) are in ALBENDAZOLE? | ALBENDAZOLE excipients list |
| DailyMed Link: | ALBENDAZOLE at DailyMed |
Recent Clinical Trials for ALBENDAZOLE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Kintampo Health Research Centre, Ghana | N/A |
| Public Health Laboratory Ivo de Carneri | Phase 3 |
| National Public Health Institute of Liberia | Phase 2 |
Pharmacology for ALBENDAZOLE
| Drug Class | Anthelmintic |
| Mechanism of Action | Cytochrome P450 1A Inducers |
Medical Subject Heading (MeSH) Categories for ALBENDAZOLE
Anatomical Therapeutic Chemical (ATC) Classes for ALBENDAZOLE
US Patents and Regulatory Information for ALBENDAZOLE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actavis Elizabeth | ALBENDAZOLE | albendazole | TABLET;ORAL | 208094-001 | May 20, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Msn | ALBENDAZOLE | albendazole | TABLET;ORAL | 213435-001 | Jan 21, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Cipla Ltd | ALBENDAZOLE | albendazole | TABLET;ORAL | 210434-001 | Sep 21, 2018 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Strides Pharma | ALBENDAZOLE | albendazole | TABLET;ORAL | 210011-001 | Dec 7, 2018 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alembic | ALBENDAZOLE | albendazole | TABLET;ORAL | 215652-001 | Sep 4, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Chartwell Rx | ALBENDAZOLE | albendazole | TABLET;ORAL | 211636-001 | Jun 10, 2020 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Edenbridge Pharms | ALBENDAZOLE | albendazole | TABLET;ORAL | 211117-001 | May 14, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
